Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] closed the trading session at $1.91.
The stocks have a year to date performance of 24.84 percent and weekly performance of 17.18 percent. The stock has been moved at 17.90 percent over the last six months. The stock has performed 17.90 percent around the most recent 30 days and changed -8.61 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 2.77M shares, LXRX reached to a volume of 3152118 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Lexicon Pharmaceuticals Inc [LXRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXRX shares is $6.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXRX stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Lexicon Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 17, 2024. While these analysts kept the previous recommendation, Leerink Partners raised their target price to Outperform. The new note on the price target was released on April 30, 2024, representing the official price target for Lexicon Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $3, while Jefferies analysts kept a Hold rating on LXRX stock.
The Average True Range (ATR) for Lexicon Pharmaceuticals Inc is set at 0.10, with the Price to Sales ratio for LXRX stock in the period of the last 12 months amounting to 189.68. The Price to Book ratio for the last quarter was 2.88, with the Price to Cash per share for the same quarter was set at 0.86.
LXRX stock trade performance evaluation
Lexicon Pharmaceuticals Inc [LXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.18. With this latest performance, LXRX shares gained by 17.90% in over the last four-week period, additionally plugging by 17.90% over the last 6 months – not to mention a rise of 40.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LXRX stock in for the last two-week period is set at 68.98, with the RSI for the last a single of trading hit 78.85, and the three-weeks RSI is set at 61.89 for Lexicon Pharmaceuticals Inc [LXRX]. The present Moving Average for the last 50 days of trading for this stock 1.6732, while it was recorded at 1.7840 for the last single week of trading, and 1.8920 for the last 200 days.
Lexicon Pharmaceuticals Inc [LXRX]: An insightful look at the core fundamentals
Lexicon Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.49 and a Current Ratio set at 11.51.
Earnings per share (EPS) analysis for Lexicon Pharmaceuticals Inc [LXRX] stock
With the latest financial reports released by the company, Lexicon Pharmaceuticals Inc posted -0.21/share EPS, while the average EPS was predicted by analysts to be reported at -0.21/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LXRX.
Lexicon Pharmaceuticals Inc [LXRX]: Institutional Ownership
There are presently around $79.26%, or 80.18%% of LXRX stock, in the hands of institutional investors. The top three institutional holders of LXRX stocks are: ARTAL GROUP S.A. with ownership of 175.1 million shares, which is approximately 71.3555%. FMR LLC, holding 38.69 million shares of the stock with an approximate value of $$64.99 million in LXRX stocks shares; and FMR LLC, currently with $$16.62 million in LXRX stock with ownership which is approximately 4.0304%.
